Bailey John E. (Jack) Jr.'s Form 4 filing
G1 Therapeutics, Inc. (GTHX) · filed Jan 8, 2024
- Accession no.
- 0001562180-24-000324
- Filed
- Jan 8, 2024
- Trade date
- Jan 3, 2024
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $36.5K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bailey John E. (Jack) Jr.CIK 0001806147 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2024 | Common Stock | AGrant or awardAcquired | +100,700 | $0.00F2 | $0 | 501,280 | Direct | |
| Jan 3, 2024 | Common Stock | SSaleDisposed | −2,592 | $3.12F5 | −$8,087.04 | 498,688 | Direct | |
| Jan 3, 2024 | Common Stock | SSaleDisposed | −9,094 | $3.12F5 | −$28,373.28 | 489,594 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2024 | Common Stock | AGrant or awardAcquired | +201,300 | $0.00 | $0 | 201,300 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each RSU represents a contingent right to receive one share of Issuer common stock.
Referenced by the price of 1 transaction in Table I.
- F5
The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
Remarks
Note: On January 3, 2024 the reporting person was also granted performance-based restricted stock units that are subject to material conditions beyond the reporting person's control, and, therefore, not considered derivative securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and excluded from this report.